Literature DB >> 18765024

Workload and resource implications of upper gastrointestinal cancer surgical centralisation in South East Wales.

M A Morgan1, M Goodson, X Escofet, G W B Clark, W G Lewis.   

Abstract

INTRODUCTION: The aim of this study was to determine whether one specialist unit could manage all patients diagnosed with oesophagogastric cancer in Gwent and Cardiff and Vale NHS Trusts over a 6-month period with regard to workload, resource and training opportunities. PATIENTS AND METHODS: All patients diagnosed with oesophagogastric (OG) cancer in Gwent and Cardiff and Vale NHS Trusts and referred to the regional South East Wales Upper GI multidisciplinary team over the 6-month period from 1 July to 31 December 2005 were studied prospectively and compared with the previous 6-month caseload at Cardiff and Vale.
RESULTS: Out-patient workload increased from 160 new (33 OG cancers) and 533 follow-up patients (161 OG cancers) between 1 January and 30 June 2005, to 290 new (68 OG cancers, 106% increase) and 865 follow-up patients (230 OG cancers, 43% increase) between 1 July, and 31 December 2005. The number of patients undergoing radical surgery increased from 14 to 23 (D2 gastrectomy 8 versus 13; oesophagectomy 6 versus 10). Cancer-related workload in the latter period generated 118 intermediate equivalents (IEs) of operative work for two specialist surgeons and one SpR occupying 38% of the total time available on 104 scheduled operating lists, compared with 64 IEs in the previous 6 months, representing an 84% increase in cancer-related operative training opportunities.
CONCLUSIONS: Centralisation of oesophagogastric cancer surgery is feasible and desirable if national guidelines are to be satisfied, and this strategy has significant positive implications for surgical training and audit.

Entities:  

Mesh:

Year:  2008        PMID: 18765024      PMCID: PMC2647237          DOI: 10.1308/003588408X301127

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  16 in total

1.  Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer.

Authors:  M R Stephens; W G Lewis; A E Brewster; I Lord; G R J C Blackshaw; I Hodzovic; G V Thomas; S A Roberts; T D L Crosby; C Gent; M C Allison; K Shute
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

2.  The present position of carcinoma of the oesophagus.

Authors:  N C TANNER
Journal:  Postgrad Med J       Date:  1947-03       Impact factor: 2.401

3.  The influence of surgeon case volume on outcome in site-specific cancer surgery.

Authors:  R J Steele
Journal:  Eur J Surg Oncol       Date:  1996-06       Impact factor: 4.424

4.  Effect of surgical experience on the results of resection for oesophageal carcinoma.

Authors:  H R Matthews; D J Powell; C C McConkey
Journal:  Br J Surg       Date:  1986-08       Impact factor: 6.939

5.  Centralisation of oesophagogastric cancer services: can specialist units deliver?

Authors:  M J Forshaw; J A Gossage; J Stephens; D Strauss; A J Botha; S Atkinson; R C Mason
Journal:  Ann R Coll Surg Engl       Date:  2006-10       Impact factor: 1.891

6.  Operable esophageal cancer: current results from the West.

Authors:  A Watson
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

7.  Transhiatal esophagectomy without thoracotomy for carcinoma of the thoracic esophagus.

Authors:  M B Orringer
Journal:  Ann Surg       Date:  1984-09       Impact factor: 12.969

8.  Gastric cancer: a curable disease in Britain.

Authors:  H M Sue-Ling; D Johnston; I G Martin; M F Dixon; M R Lansdown; M J McMahon; A T Axon
Journal:  BMJ       Date:  1993-09-04

9.  Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985.

Authors:  P McCulloch
Journal:  Br J Surg       Date:  1994-03       Impact factor: 6.939

10.  Learning curve for oesophageal cancer surgery.

Authors:  D N Sutton; J Wayman; S M Griffin
Journal:  Br J Surg       Date:  1998-10       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.